CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [***] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. ASSET PURCHASE AGREEMENTConfidential Treatment • November 6th, 2013 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of August 8, 2013 (the “Effective Date”), is entered into by and among NOVEL DRUG SOLUTIONS LLC, a New Jersey limited liability company (“NDS”), with a place of business at 540 State Route 10, Suite 3, Randolph, New Jersey 07869, and EYE CARE NORTHWEST, PA, a New Jersey profession association (“ECNW”, each of NDS and ECNW a “Seller” and collectively the “Sellers”), with a place of business at 350 Sparta Ave., Bldg A, Sparta, New Jersey 07871, and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12626 High Bluff Drive, Suite 150, San Diego, California 92130. The parties hereby agree as follows:
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 6th, 2013 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amendment to Asset Purchase Agreement, dated as of October 14, 2013 (the “Amendment”), is entered into by and among NOVEL DRUG SOLUTIONS LLC, a New Jersey limited liability company (“NDS”), and EYE CARE NORTHWEST, PA, a New Jersey profession association (“ECNW”, each of NDS and ECNW a “Seller” and collectively the “Sellers”), and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis” and together with NDS and ECNW, the “Parties”, and each, a “Party”).
